Table 10 Occurrence of adverse events suggestive of heart failure in 24 placebo-controlled trials of linagliptin

Cardiac failure (narrow SMQ)*, n (%)

26 (0.5)

8 (0.2)

Acute pulmonary edema

1 (0.0)

1 (0.0)

Cardiac failure

6 (0.1)

2 (0.1)

Cardiac failure, acute

2 (0.0)

0 (0.0)

Cardiac failure, chronic

1 (0.0)

0 (0.0)

Cardiac failure, congestive

7 (0.1)

5 (0.2)

Cardiogenic shock

2 (0.0)

0 (0.0)

Cardiopulmonary failure

1 (0.0)

0 (0.0)

Left ventricular failure

6 (0.1)

0 (0.0)

Pulmonary edema

1 (0.0)

2 (0.1)

Right ventricular failure

1 (0.0)

0 (0.0)